NDA 215712 · Perrigo Pharma Intl
Nasonex 24hr Allergy
Mometasone Furoate · Nasal
Last checked: Nov 19, 2026Latest source record: Jun 7, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Mar 17, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
251
94 Phase 3, 12 recruiting
FAERS reports
33,486
21,622 serious, 1,466 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 10, 2026.
Uses temporarily relieves these symptoms of hay fever or other upper respiratory allergies: • nasal congestion • runny nose • sneezing • itchy nose
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- NASONEX 24HR ALLERGY · MOMETASONE FUROATE 0.05MG/SPRAY · SPRAY, METERED, NASAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Mometasone Furoate" as an intervention, any sponsor and status, largest first.
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Individualizing Treatment for Asthma in Primary Care (Full Study)Pivotal-lookingRecruiting
DARTNet InstituteGovernment (non-federal)
NCT07052942 · 3,200 participants (planned) · Start Aug 1, 2025 · Primary completion Nov 15, 2029
Drug: Inhaled corticosteroid (ICS); Azithromycin · For: Asthma; Asthma Attack; Asthma Exacerbations
Sites: Aurora, Colorado; Orlando, Florida; Kansas City, Kansas · 13 sites in all
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02571777 · 3,092 participants · Start Dec 8, 2015 · Primary completion Jun 14, 2019
Drug: QVM149 150/50/160; QVM149 150/50/80 and 3 more · For: Asthma
Sites: Bahía Blanca, Argentina; CABA, Argentina; Florida, Argentina · 403 sites in all
- Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00941798 · 2,283 participants · Start Jul 2009 · Primary completion May 2011
Drug: QMF149 Twisthaler®; Mometasone Twisthaler® · For: Asthma
Sites: Birmingham, Alabama; Buena Park, California; Encinitas, California · 146 sites in all
- A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02554786 · 2,216 participants · Start Dec 29, 2015 · Primary completion Nov 21, 2018
Drug: Indacaterol acetate/Mometasone furoate; Mometasone furoate and 1 more · For: Asthma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 388 sites in all
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)Pivotal-lookingCompleted
ALK-Abelló A/SIndustry
NCT01700192 · 1,482 participants · Start Jan 2013 · Primary completion Apr 2015
Drug: MK-8237 tablets; Placebo tablets and 4 more · For: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
- Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + TiotropiumPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03158311 · 1,426 participants · Start Feb 5, 2018 · Primary completion Jul 12, 2019
Drug: QVM149; Salmeterol/fluticasone plus tiotropium · For: Asthma
Sites: Berazategui, Argentina; CABA, Argentina; Caba, Argentina · 163 sites in all
- A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female VolunteersPivotal-lookingCompleted
Mylan Pharmaceuticals IncIndustry
NCT02109185 · 1,307 participants · Start Sep 2013 · Primary completion Oct 2013
Drug: Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.; Nasonex® Nasal Spray, 50 μg/actuation and 2 more · For: Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea3,231
- drug ineffective2,703
- headache2,677
- asthma2,505
- fatigue2,386
- cough2,265
- nausea2,176
- pain1,780
- wheezing1,745
- pneumonia1,597
- off label use1,595
- gastrooesophageal reflux disease1,581
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 367 |
| 2005 | 465 |
| 2006 | 542 |
| 2007 | 612 |
| 2008 | 689 |
| 2009 | 783 |
| 2010 | 1,050 |
| 2011 | 1,076 |
| 2012 | 1,550 |
| 2013 | 1,881 |
| 2014 | 1,842 |
| 2015 | 2,219 |
| 2016 | 2,493 |
| 2017 | 1,627 |
| 2018 | 1,993 |
| 2019 | 2,201 |
| 2020 | 2,036 |
| 2021 | 1,949 |
| 2022 | 1,972 |
| 2023 | 1,867 |
| 2024 | 1,606 |
| 2025 | 1,543 |
| 2026 | 1,122 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of various corticosteroids in the treatment of children with allergic rhinitis: A systematic review and network meta-analysis.
Li Y, Xiong J, Zhang Z, et al. · J Evid Based Med 2024 · Systematic Review, Network Meta-Analysis
- Hypothalamic-pituitary-adrenal axis suppression and intranasal corticosteroid use: A systematic review and meta-analysis.
Sampieri G, Namavarian A, Lee JJW, et al. · Int Forum Allergy Rhinol 2022 · Meta-Analysis, Systematic Review
- Comparative Efficacy of Mometasone Nasal Spray Combined with Different Doses of Desloratadine, and Montelukast in Childhood Allergic Rhinitis: A Randomized Clinical Trial.
Ghanbari N, Eftekhari K, Samadzadeh-Mamaghani M, et al. · Iran J Allergy Asthma Immunol 2024 · Randomized Controlled Trial, Comparative Study
- Epistaxis Risk Associated with Intranasal Corticosteroid Sprays: A Systematic Review and Meta-analysis.
Wu EL, Harris WC, Babcock CM, et al. · Otolaryngol Head Neck Surg 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients.
Patel C, Sheth V, Koppula R, et al. · Respir Med 2025 · Clinical Trial, Phase III, Equivalence Trial
- Efficacy of montelukast for adenoid hypertrophy in paediatrics: A systematic review and meta-analysis.
Alanazi F, Alruwaili M, Alanazy S, et al. · Clin Otolaryngol 2024 · Systematic Review, Meta-Analysis
Sponsor: Perrigo Pharma Intl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.